4120 Stock Overview
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Orient EuroPharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$41.05 |
| 52 Week High | NT$48.30 |
| 52 Week Low | NT$35.65 |
| Beta | 0.34 |
| 1 Month Change | -2.15% |
| 3 Month Change | 6.62% |
| 1 Year Change | 12.47% |
| 3 Year Change | -14.12% |
| 5 Year Change | -28.48% |
| Change since IPO | 226.00% |
Recent News & Updates
Recent updates
Here's Why Orient EuroPharma (GTSM:4120) Has A Meaningful Debt Burden
Apr 04
Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) 3.3% Dividend Worth Your Time?
Mar 04A Look At Orient EuroPharma's (GTSM:4120) Share Price Returns
Feb 10Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) Recent Performancer Underpinned By Weak Financials?
Jan 22We Think Orient EuroPharma (GTSM:4120) Can Stay On Top Of Its Debt
Jan 04
A Look At The Fair Value Of Orient EuroPharma Co., Ltd. (GTSM:4120)
Dec 17Are Dividend Investors Getting More Than They Bargained For With Orient EuroPharma Co., Ltd.'s (GTSM:4120) Dividend?
Nov 29Shareholder Returns
| 4120 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.1% | -8.2% | -5.7% |
| 1Y | 12.5% | 3.8% | 23.8% |
Return vs Industry: 4120 exceeded the TW Pharmaceuticals industry which returned 3.8% over the past year.
Return vs Market: 4120 underperformed the TW Market which returned 23.8% over the past year.
Price Volatility
| 4120 volatility | |
|---|---|
| 4120 Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.5% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4120 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4120's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | n/a | Peter Tsai | www.oepgroup.com |
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name.
Orient EuroPharma Co., Ltd. Fundamentals Summary
| 4120 fundamental statistics | |
|---|---|
| Market cap | NT$3.56b |
| Earnings (TTM) | NT$143.94m |
| Revenue (TTM) | NT$4.59b |
24.7x
P/E Ratio0.8x
P/S RatioIs 4120 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4120 income statement (TTM) | |
|---|---|
| Revenue | NT$4.59b |
| Cost of Revenue | NT$2.44b |
| Gross Profit | NT$2.15b |
| Other Expenses | NT$2.00b |
| Earnings | NT$143.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.66 |
| Gross Margin | 46.76% |
| Net Profit Margin | 3.13% |
| Debt/Equity Ratio | 105.4% |
How did 4120 perform over the long term?
See historical performance and comparison